


RESEARCH ARTICLE

Novel biphenyl ester derivatives as tyrosinase inhibitors: Synthesis, crystallographic, spectral analysis and molecular docking studies

Huey Chong Kwong¹, C. S. Chidan Kumar^{2*}, Siau Hui Mah³, Tze Shyang Chia⁴, Ching Kheng Quah^{4*}, Zi Han Loh³, Siddegowda Chandraju⁵, Gin Keat Lim¹

1 School of Chemical Sciences, Universiti Sains Malaysia, Penang, Malaysia, **2** Department of Engineering Chemistry, Vidya Vikas Institute of Engineering & Technology, Visvesvaraya Technological University, Alanahalli, Mysuru, Karnataka, India, **3** School of Biosciences, Taylor's University, Lakeside Campus, Subang Jaya, Selangor, Malaysia, **4** X-ray Crystallography Unit, School of Physics, Universiti Sains Malaysia, Penang, Malaysia, **5** Department of Sugar Technology & Chemistry, Sir M.V. PG Center, University of Mysore, Tubinakere, India

* ckquah@usm.my (CKQ); chidankumar@gmail.com (CSCK)


 OPEN ACCESS

Citation: Kwong HC, Chidan Kumar CS, Mah SH, Chia TS, Quah CK, Loh ZH, et al. (2017) Novel biphenyl ester derivatives as tyrosinase inhibitors: Synthesis, crystallographic, spectral analysis and molecular docking studies. PLoS ONE 12(2): e0170117. doi:10.1371/journal.pone.0170117

Editor: Mohammad Shahid, Aligarh Muslim University, INDIA

Received: November 2, 2016

Accepted: December 29, 2016

Published: February 27, 2017

Copyright: © 2017 Kwong et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All spectral and tyrosinase assay data are already available in the manuscript and supporting information files. Three dimensional crystallography data are deposited in the Cambridge Crystallographic Data Centre with CCDC no. 1476974-1476982 and 1477101-1477107 as supplementary publications. Copies of available material can be obtained free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (Fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).

Abstract

Biphenyl-based compounds are clinically important for the treatments of hypertension and inflammatory, while many more are under development for pharmaceutical uses. In the present study, a series of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl benzoates, **2(a-q)**, and 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl pyridinecarboxylate, **2(r-s)** were synthesized by reacting 1-([1,1'-biphenyl]-4-yl)-2-bromoethan-1-one with various carboxylic acids using potassium carbonate in dimethylformamide at ambient temperature. Single-crystal X-ray diffraction studies revealed a more closely packed crystal structure can be produced by introduction of biphenyl moiety. Five of the compounds among the reported series exhibited significant anti-tyrosinase activities, in which **2p**, **2r** and **2s** displayed good inhibitions which are comparable to standard inhibitor kojic acid at concentrations of 100 and 250 µg/mL. The inhibitory effects of these active compounds were further confirmed by computational molecular docking studies and the results revealed the primary binding site is active-site entrance instead of inner copper binding site which acted as the secondary binding site.

Introduction

Biphenyl are two adjoined benzene rings that attached through their 1,1'-positions. It appeared as a white crystal with pleasant odor, which served as an important structure analog in various synthesis. The most widely used biphenyl derivatives is polychlorinated biphenyls (PCBs) in electrical and chemical industries as dielectric fluids and heat transfer agents [1]. Biphenyl moiety also served as central building block for basic liquid crystal [2] and fluorescent layers in OLEDs [3]. As for pharmaceutical uses, to date, there are two simple biphenyl derivatives which have been applied in clinical usage to treat hypertension [4] and inflammatory [5]; and many more are in development as potential anti-cholinesterase [6], anti-diabetic [7], anti-tumor [8], anti-cancer [9] and anti-leukemia agent [10], and as a potential therapeutics for

Funding: HCK thanks Malaysian Government for MyBrain15 (MyPhD) scholarship and wishes to offer his deep gratitude to Ivy Ye Wei Ng, student from School of Biosciences, Taylor's University, Malaysia, for anti-tyrosinase assay data collection. The authors thank the Malaysian Government and Universiti Sains Malaysia (USM) for Fundamental Research Grant Scheme (FRGS) (203-PFIZIK.6711563).

Competing interests: The authors have declared that no competing interests exist.

cardiovascular disease [11] and osteoporosis [12]. The anti-tyrosinase activities of biphenyl-based compounds were also reported [13–15]. Tyrosinase (EC 1.14.18.1) is a multi-functional copper-containing enzyme that plays a crucial role in melanin biosynthesis and melanin contributes to skin pigmentation. Therefore, tyrosinase inhibitors were useful in the treatment of dermatological disorder that associated with melanin hyperpigmentation, in cosmetic for whitening and in depigmentation after sunburn [16]. The biological activities of biphenyl derivatives and their use as tyrosinase inhibitor inspired us to work on the synthesis of a series of new biphenyl esters and to evaluate their anti-tyrosinase activities. In the current project, we focused on the design and synthesis of new anti-tyrosinase agents with biphenyl-based structure to reach more active analogs towards inhibition of tyrosinase. Besides, we hope the new analogs to render minimum side effects. We also investigated in-silico binding mode of the proposed ligands into tyrosinase enzyme in comparison with kojic acid as reference drug by docking procedure. In fact, it revealed biphenyl-based derivatives have similar pharmacophoric pattern like kojic acid and are able to bind at the active-site entrance.

Material and methods

All reagents and solvents were obtained commercially from Sigma Aldrich Corporation with high purity. Melting points were determined on Stuart (UK) SMP10 apparatus. ^1H and ^{13}C nuclear magnetic resonance (NMR) spectra were recorded in CDCl_3 at 500 MHz and 125 MHz, respectively, using Bruker Avance III 500 spectrometer. Fourier transform infrared spectroscopy (FTIR) spectra were recorded on Perkin Elmer Frontier FTIR spectrometer equipped with attenuated total reflection (ATR). The X-ray diffraction analysis were performed using Bruker APEX II DUO CCD diffractometer, employing $\text{MoK}\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$) with φ and ω scans. Data reduction and absorption correction were performed using SAINT and SADABS program [17]. All X-ray structures were solved by using direct methods and refined by using full-matrix least-squares techniques on F^2 through SHELXTL software package [18]. The C-bound H atoms were calculated geometrically with isotropic displacement parameters set to 1.2 times the equivalent isotropic U value of the parent carbon atoms. N-bound H atoms are located from difference Fourier map and refined freely [$\text{N}—\text{H} = 0.87(3)–0.93(3) \text{ \AA}$]. Similar geometry restraint (SAME) was applied to disordered biphenyl moiety of **2n**. Crystallographic data for **2b–2e**, **2g** and **2i–2s** were deposited in the Cambridge Crystallographic Data Centre with CCDC no. 1476974–1476982 and 1477101–1477107 as supplementary publications. Copies of available material can be obtained free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (Fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).

Synthesis

Target compounds were synthesized *via* a two-step reaction (Fig 1). First, 1-([1,1'-biphenyl]-4-yl)ethan-1-one was refluxed with *N*-bromosuccinimide and petroleum ether in methanol at 333K for two hours. The resultant precipitate of 1-([1,1'-biphenyl]-4-yl)-2-bromoethan-1-one (**1**) was filtered and recrystallized with ethanol. Next, **1** (0.55 g, 0.002 mol) was reacted with various carboxylic acids (0.003 mol) in the presence of potassium carbonate in DMF (5 ml) and stirred at room temperature for about four hours. The reaction progress was monitored by thin layer chromatography (TLC). The reaction mixture was poured into ice-cool water after the completion of reaction and was stirred for another 10 minutes. The precipitate obtained was filtered out and washed successively with distilled water [19]. The dried precipitate was purified using silica gel column chromatography, eluting with ethyl acetate/hexane (2:8). Suitable single crystal specimens were obtained *via* slow evaporation from various types




Fig 1. The reaction scheme for the synthesis of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl benzoates, **2(a-q)**, and 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl pyridinecarboxylate, **2r&2s**.

doi:10.1371/journal.pone.0170117.g001

of solvents as described below. All target compounds **2(a-s)** were synthesized in good yield and high purity. Their chemical structures were characterized by using NMR and FTIR spectroscopy. Crystal structures of all compounds except **2a**, **2f** and **2h** were determined by using single-crystal X-ray diffraction analysis.

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl benzoate (2a): Yield: 73%; M.P. 442–444 K; FT-IR (ATR (solid) cm^{-1}): 3063 (Ar C–H, ν), 2936 (C–H, ν), 1718, 1696 (C=O, ν), 1599, 1451 (Ar, C–C, ν), 1277, 1234, 1123 (C–O, ν); ^1H NMR (500 MHz, CDCl_3): δ ppm δ 8.197–8.180 (d, 2H, $J = 8.3$ Hz, 17–CH, 21–CH), 8.090–8.073 (d, 2H, $J = 8.6$ Hz, 9–CH, 11–CH), 7.769–7.752 (d, 2H, $J = 8.6$ Hz, 8–CH, 12–CH), 7.675–7.661 (d, 2H, $J = 7.1$ Hz, 1–CH, 5–CH), 7.649–7.620 (t, 1H, $J = 7.4$ Hz, 19–CH), 7.530–7.496 (m, 4H, 2–CH, 4–CH, 18–CH, 20–CH), 7.463–7.434 (t, 1H, $J = 7.1$ Hz, 3–CH), 5.641 (s, 2H, 14– CH_2); ^{13}C NMR (125 MHz, CDCl_3): δ 191.77 (C13), 166.11 (C15), 146.62 (C7), 139.68 (C6), 133.39 (C19), 133.01 (C10), 130.02 (C9, C11), 129.44 (C16), 129.03 (C2, C4), 128.48 (C17, C21), 128.47 (C18, C20), 127.91 (C3), 127.53 (C8, C12), 127.31 (C1, C5), 66.53 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 2-chlorobenzoate (2b): Solvent for growing crystal: acetone; Yield: 85%; M.P. 392–394 K; FT-IR (ATR (solid) cm^{-1}): 3068 (Ar C–H, ν) 2944 (C–H, ν), 1728, 1691 (C=O, ν), 1589, 1470 (Ar, C–C, ν), 1234, 1112, 1029 (C–O, ν), 736 (C–Cl, ν); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.111–8.097 (d, 1H, $J = 7.3$ Hz, 21–CH), 8.085–8.068 (d, 2H, $J = 8.6$ Hz, 9–CH, 11–CH), 7.776–7.758 (d, 2H, $J = 8.6$ Hz, 8–CH, 12–CH), 7.681–7.664 (d, 2H, $J = 8.4$ Hz, 1–CH, 5–CH), 7.533–7.503 (m, 3H, 2–CH, 3–CH, 4–CH), 7.495–7.479 (d, 1H,

$J = 7.3$ Hz, 18-CH), 7.466–7.437 (t, 1H, $J = 7.4$ Hz, 20-CH), 7.417–7.388 (t, 1H, $J = 7.3$ Hz, 19-CH), 5.656 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 191.43 (C13), 165.27 (C15), 146.76 (C7), 140.26 (C6), 138.46 (C10), 134.14 (C19), 133.04 (C17), 132.88 (C16), 132.00 (C20), 131.24 (C3), 129.10 (C9, C11), 128.49 (C2, C4), 128.27 (C18), 127.59 (C8, C12), 127.35 (C1, C5), 126.78 (C21) 66.55 (C14)

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 3-chlorobenzoate (2c): Solvent for growing crystal: acetone; Yield: 80%; M.P. 427–429 K; FT-IR (ATR (solid) cm⁻¹): 3076 (Ar C-H, v), 2941 (C-H, v), 1727, 1696 (C = O, v), 1600, 1412 (Ar, C-C, v), 1295, 1232, 1131 (C-O, v), 744 (C-Cl, v); ¹H NMR (500 MHz, CDCl₃): δ ppm 8.169 (s, 1H, 17-CH), 8.080–8.063 (d, 3H, $J = 8.6$ Hz, 9-CH, 11-CH, 21-CH), 7.774–7.757 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.676–7.662 (d, 2H, $J = 7.1$ Hz, 1-CH, 5-CH), 7.618–7.600 (d, 1H, $J = 9.1$ Hz, 19-CH), 7.534–7.504 (t, 2H, $J = 7.1$ Hz, 2-CH, 4-CH), 7.473–7.441 (m, 2H, 3-CH, 20-CH), 5.651 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 191.31 (C13), 164.94 (C15), 146.76 (C7), 139.62 (C6), 134.66 (C10), 133.44 (C19), 132.81 (C10), 131.17 (C16), 130.08 (C20), 129.82 (C17), 129.05 (C9, C11), 128.50 (C21), 128.44 (C2, C4), 128.15 (C3), 127.58 (C8, C12), 127.32 (C1, C5) 66.72 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-chlorobenzoate (2d): Solvent for growing crystal: acetone, acetonitrile (1:1 v/v); Yield: 84%; M.P. 435–437 K; FT-IR (ATR (solid) cm⁻¹): 3066 (Ar C-H, v), 2944 (C-H, v), 1719, 1690 (C = O, v), 1598, 1425 (Ar, C-C, v), 1274, 1232, 1107 (C-O, v), 760 (C-Cl, v); ¹H NMR (500 MHz, CDCl₃): δ ppm 8.134–8.116 (d, 2H, $J = 8.8$ Hz, 17-CH, 21-CH), 8.080–8.063 (d, 2H, $J = 8.6$ Hz, 9-CH, 11-CH), 7.772–7.755 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.675–7.661 (d, 2H, $J = 7.1$ Hz, 1-CH, 5-CH), 7.533–7.503 (t, 2H, $J = 7.1$ Hz, 2-CH, 4-CH), 7.498–7.480 (d, 2H, $J = 8.8$ Hz, 18-CH, 20-CH), 7.467–7.437 (t, 1H, $J = 7.1$ Hz, 3-CH), 5.639 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 191.52 (C13), 16532 (C15), 146.77 (C7), 139.95 (C6), 139.66 (C19), 132.93 (C10), 131.44 (C9, C11), 129.05 (C17, C21), 128.86 (C18, C20), 128.50 (C16), 128.44 (C2, C4), 127.89 (C3), 127.57 (C8, C12), 127.32 (C1, C5), 66.61 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 2,4-dichlorobenzoate (2e): Solvent for growing crystal: chloroform; Yield: 79%; M.P. 383–385 K; FT-IR (ATR (solid) cm⁻¹): 3092 (Ar C-H, v), 2933 (C-H, v), 1735, 1693 (C = O, v), 1603, 1415 (Ar, C-C, v), 1229, 1134, 1105 (C-O, v), 763 (C-Cl, v); ¹H NMR (500 MHz, CDCl₃): δ ppm 8.078–8.052 (m, 3H, 9-CH, 11-CH, 17-CH), 7.769–7.752 (d, 2H, $J = 8.5$ Hz, 8-CH, 12-CH), 7.672–7.658 (d, 2H, $J = 7.1$ Hz, 1-CH, 5-CH), 7.546 (s, 1H, 20-CH), 7.530–7.500 (t, 2H, $J = 7.1$ Hz, 2-CH, 4-CH), 7.465–7.436 (t, 1H, $J = 7.1$ Hz, 3-CH), 7.392–7.375 (d, 1H, $J = 8.5$ Hz, 18-CH), 5.644 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 191.17 (C13), 164.05 (C15), 146.79 (C7), 139.58 (C6), 138.84 (C19), 135.38 (C10), 133.09 (C21), 132.75 (C17), 131.11 (C18), 139.05 (C9, C11), 128.52 (C20), 128.43 (C2, C4), 127.57 (C8, C12), 127.50 (C16), 127.31 (C1, C5), 127.14 (C3), 66.74 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 2-methylbenzoate (2f): Yield: 68%; M.P. 368–370 K; FT-IR (ATR (solid) cm⁻¹): 3063 (Ar C-H, v), 2931 (C-H, v), 1723, 1696 (C = O, v), 1605, 1419 (Ar, C-C, v), 1263, 1234, 1099 (C-O, v); ¹H NMR (500 MHz, CDCl₃): δ ppm 8.126–8.112 (d, 1H, $J = 7.3$ Hz, 21-CH), 8.091–8.073 (d, 2H, $J = 8.6$ Hz, 9-CH, 11-CH), 7.770–7.753 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.677–7.663 (d, 2H, $J = 7.1$ Hz, 1-CH, 5-CH), 7.530–7.500 (t, 2H, $J = 7.1$ Hz, 2-CH, 4-CH), 7.485–7.433 (m, 3H, 3-CH, 18-CH), 7.331–7.301 (t, 2H, $J = 7.3$ Hz, 19-CH, 20-CH), 5.621 (s, 2H, 14-CH₂), 2.679 (s, 3H, 22-CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 189.12 (C13), 164.05 (C15), 146.67 (C7), 140.69 (C6), 139.55 (C17), 133.05 (C10), 132.40 (C19), 131.72 (C18), 131.03 (C21), 129.03 (C9, C11), 128.85 (C16), 128.45 (C2, C4), 127.71 (C3), 127.53 (C8, C12), 127.31 (C1, C5), 125.81 (C20), 66.28 (C14), 21.71 (C22).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 3-methylbenzoate (2g): Solvent for growing crystal: acetone, ethanol and acetonitrile (1:1:1 v/v/v); Yield: 79%; M.P. 413–415 K; FT-IR (ATR (solid) cm⁻¹): 3033 (Ar C-C, v), 2942 (C-H, v), 1712, 1696 (C = O, v), 1602, 1416, (Ar, C-H, v), 1279,

1196, 1118 (C–O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm δ 8.090–8.073 (d, 2H, $J = 8.6$ Hz, 9–CH, 11–CH), 8.008 (s, 1H, 17–CH), 7.997–7.981 (d, 1H, $J = 7.8$ Hz, 21–CH), 7.768–7.751 (d, 2H, $J = 8.6$ Hz, 8–CH, 12–CH), 7.676–7.660 (d, 2H, $J = 7.5$ Hz, 1–CH, 5–CH), 7.531–7.501 (t, 2H, $J = 7.5$ Hz, 2–CH, 4–CH), 7.464–7.434 (m, 2H, 19–CH, 20–CH), 7.410–7.380 (t, 1H, $J = 7.5$ Hz, 3–CH), 5.633 (s, 2H, 14– CH_2), 2.454 (s, 3H, 22– CH_3); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 191.81 (C13), 166.28 (C15), 146.62 (C7), 139.68 (C6), 138.29 (C18), 134.17 (C19), 133.02 (C10), 130.52 (C21), 129.33 (C16), 129.03 (C9, C11), 128.47 (C2, C4), 128.45 (C17), 128.39 (C20), 127.53 (C8, C12), 127.32 (C1, C5), 127.17 (C3), 66.45 (C14), 21.30 (C22).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-methylbenzoate (2h): Yield: 71%; M.P. 438–440 K; FT-IR (ATR (solid) cm^{-1}): 3038 (Ar C–H, v), 2928 (C–H, v), 1715, 1696 (C = O, v), 1602, 1411 (Ar, C–C, v), 1274, 1234, 1129 (C–O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.086–8.065 (m, 4H, 9–CH, 11–CH, 17–CH, 21–CH), 7.763–7.746 (d, 2H, $J = 8.6$ Hz, 8–CH, 12–CH), 7.673–7.659 (d, 2H, $J = 7.2$ Hz, 1–CH, 5–CH), 7.528–7.498 (t, 2H, $J = 7.2$ Hz, 2–CH, 4–CH), 7.460–7.431 (t, 1H, $J = 7.2$ Hz, 3–CH), 7.313–7.297 (d, 2H, $J = 7.9$ Hz, 18–CH, 20–CH), 5.616 (s, 2H, 14– CH_2), 2.460 (s, 3H, 22– CH_3); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 191.94 (C13), 166.15 (C15), 146.58 (C7), 144.14 (C19), 139.69 (C6), 133.05 (C10), 130.05 (C9, C11), 129.20 (C17, C21), 129.02 (C18, C20), 128.47 (C2, C4), 128.44 (C3), 127.52 (C8, C12), 127.31 (C1, C5), 126.67 (C16), 66.38 (C14), 21.35 (C22).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 2-methoxybenzoate (2i): Solvent for growing crystal: acetone; Yield: 85%; M.P. 400–402 K; FT-IR (ATR (solid) cm^{-1}): 3073 (Ar C–H, v), 2998, 2936, 2843 (C–H, v), 1731, 1699 (C = O, v), 1599, 1411 (Ar, C–H, v), 1244, 1225, 1102, 1016 (C–O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.088–8.072 (d, 2H, $J = 8.3$ Hz, 9–CH, 11–CH), 8.059–8.044 (d, 1H, $J = 7.6$ Hz, 17–CH), 7.762–7.745 (d, 2H, $J = 8.3$ Hz, 8–CH, 12–CH), 7.674–7.660 (d, 2H, $J = 7.2$ Hz, 1–CH, 5–CH), 7.565–7.550 (d, 1H, $J = 7.6$ Hz, 20–CH), 7.529–7.498 (t, 2H, $J = 7.2$ Hz, 2–CH, 4–CH), 7.460–7.431 (t, 1H, $J = 7.2$ Hz, 3–CH), 7.070–7.031 (m, 2H, 18–CH, 19–CH), 5.603 (s, 2H, 14– CH_2), 3.957 (s, 3H, 22– CH_3); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 191.05 (C13), 165.30 (C15), 159.63 (C17), 146.50 (C7), 139.74 (C6), 134.10 (C19), 133.17 (C10), 132.30 (C21), 129.04 (C9, C11), 128.52 (C2, C4), 128.42 (C3), 127.48 (C8, C12), 127.32 (C1, C5), 120.26 (C20), 119.04 (C16), 112.09 (C18), 66.29 (C14), 56.08 (C22).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 3-methoxybenzoate (2j): Solvent for growing crystal: acetone; Yield: 84%; M.P. 397–399 K; FT-IR (ATR (solid) cm^{-1}): 3092 (Ar C–H, v), 2933, 2838 (C–H, v), 1719, 1704 (C = O, v), 1603, 1417 (Ar, C–C, v), 1288, 1110, 1030 (C–O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.088–8.071 (d, 2H, $J = 8.6$ Hz, 9–CH, 11–CH), 7.802–7.787 (d, 1H, $J = 7.5$ Hz, 21–CH), 7.769–7.752 (d, 2H, $J = 8.6$ Hz, 8–CH, 12–CH), 7.696 (s, 1H, 17–CH), 7.676–7.659 (d, 2H, $J = 7.9$ Hz, 1–CH, 5–CH), 7.531–7.501 (t, 2H, $J = 7.9$ Hz, 2–CH, 4–CH), 7.464–7.435 (t, 1H, $J = 7.5$ Hz, 20–CH), 7.431–7.399 (t, 1H, $J = 7.9$ Hz, 3–CH), 7.189–7.174 (d, 1H, $J = 7.5$ Hz, 19–CH), 5.634 (s, 2H, 14– CH_2), 3.898 (s, 3H, 22– CH_3); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 191.69 (C13), 165.99 (C15), 159.62 (C17), 146.64 (C7), 139.66 (C6), 132.98 (C10), 130.68 (C16), 129.52 (C20), 129.04 (C9, C11), 128.47 (C2, C4), 127.54 (C8, C12), 127.53 (C3), 127.32 (C1, C5), 122.49 (C19), 120.15 (C21), 114.22 (C17), 66.59 (C14), 55.49 (C22).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-methoxybenzoate (2k): Solvent for growing crystal: acetone and acetonitrile (1:1 v/v); Yield: 79%; M.P. 437–439 K; FT-IR (ATR (solid) cm^{-1}): 3005 (Ar C–H, v), 2976, 2931, 2841 (C–H, v), 1714, 1698 (C = O, v), 1603, 1420 (Ar, C–C, v), 1256, 1168, 1126, 1028 (C–O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.150–8.133 (d, 2H, $J = 9.0$ Hz, 17–CH, 21–CH), 8.087–9.070 (d, 2H, $J = 8.6$ Hz, 9–CH, 11–CH), 7.763–7.746 (d, 2H, $J = 8.6$ Hz, 8–CH, 12–CH), 7.674–7.659 (d, 2H, $J = 7.5$ Hz, 1–CH, 5–CH), 7.529–7.499 (t, 2H, $J = 7.5$ Hz, 2–CH, 4–CH), 7.461–7.432 (t, 1H, $J = 7.5$ Hz, 3–CH), 6.994–6.976 (d, 2H, $J = 9.0$ Hz, 18–CH, 20–CH), 5.605 (s, 2H, 14– CH_2), 3.910 (s, 3H, 22– CH_3); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 192.07 (C13), 165.79 (C15), 163.74 (C19), 146.56 (C7), 139.70 (C6), 133.07 (C10),

132.11 (C17, C21), 129.02 (C9, C11), 128.47 (C2, C4), 128.43 (C3), 127.51 (C8, C12), 127.31 (C1, C5), 121.80 (C16), 113.75 (C18, C20), 66.30 (C14), 55.49 (C22).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 2-nitrobenzoate (2l): Solvent for growing crystal: acetone, acetonitrile (1:1 v/v); Yield: 80%; M.P. 413–415 K; FT-IR (ATR (solid) cm^{-1}): 3092 (Ar C-H, v), 2941, 2864 (C-H, v), 1743, 1690 (C = O, v), 1603, 1423 (Ar, C-C, v), 1529, 1343 (N-O, v), 1290, 1240, 1123, 1078 (C-O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.068–8.051 (d, 2H, $J = 8.6$ Hz, 9-CH, 11-CH), 8.039–8.011 (m, 2H, 18-CH, 19-CH), 7.797–7.762 (m, 3H, 8-CH, 12-CH, 21-CH), 7.723–7.692 (t, 1H, $J = 7.9$ Hz, 20-CH), 7.681–7.660 (d, 2H, $J = 7.5$ Hz, 1-CH, 5-CH), 7.534–7.504 (t, 2H, $J = 7.5$ Hz, 2-CH, 4-CH), 7.468–7.439 (t, 1H, $J = 7.5$ Hz, 3-CH), 5.664 (s, 2H, 14- CH_2); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 190.92 (C13), 165.10 (C15), 147.79 (C7), 146.88 (C17), 139.57 (C6), 133.28 (C20), 132.62 (C10), 131.94 (C19), 130.40 (C21), 129.05 (C9, C11), 128.53 (C3), 128.45 (C2, C4), 127.61 (C8, C12), 127.37 (C16), 127.32 (C1, C5), 124.05 (C18), 67.36 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 3-nitrobenzoate (2m): Solvent for growing crystal: acetone, acetonitrile (1:1 v/v); Yield: 82%; M.P. 426–428 K; FT-IR (ATR (solid) cm^{-1}): 3092 (Ar, C-H, v), 2925, 2880 (C-H, v), 1738, 1690 (C = O, v), 1603, 1441 (Ar, C-C, v), 1537, 1348 (N-O, v), 1229, 1136 (C-O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 9.027 (s, 1H, 21-CH), 8.525–8.492 (t, 2H, $J = 8.0$ Hz, 18-CH, 19-CH), 8.085–8.068 (d, 2H, $J = 8.6$ Hz, 9-CH, 11-CH), 7.787–7.769 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.751–7.719 (t, 1H, $J = 8.0$ Hz, 17-CH), 7.680–7.666 (d, 2H, $J = 7.2$ Hz, 1-CH, 5-CH), 7.538–7.508 (t, 2H, $J = 7.2$ Hz, 2-CH, 4-CH), 7.473–7.443 (t, 1H, $J = 7.2$ Hz, 3-CH), 5.715 (s, 2H, 14- CH_2); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 190.88 (C13), 164.07 (C15), 148.35 (C18), 146.93 (C7), 139.56 (C6), 135.67 (C21), 132.63 (C10), 131.25 (C16), 129.77 (C20), 129.07 (C9, C11), 128.56 (C3), 128.44 (C2, C4), 127.82 (C19), 127.63 (C8, C12), 127.32 (C1, C5), 126.06 (C17), 67.05 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-nitrobenzoate (2n): Solvent for growing crystal: acetone, ethanol and acetonitrile (1:1:1 v/v/v); Yield: 75%; M.P. 459–461 K; FT-IR (ATR (solid) cm^{-1}): 3116 (Ar, C-H, v), 2931, 2859 (C-H, v), 1733, 1696 (C = O, v), 1603, 1420 (Ar, C-C, v), 1518, 1348 (N-O, v), 1282, 1237, 1120, 1105 (C-O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.361 (s, 4H, 17-CH, 18-CH, 20-CH, 21-CH), 8.080–8.063 (s, 2H, $J = 8.6$ Hz, 9-CH, 11-CH), 7.784–7.767 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.677–7.663 (d, 2H, $J = 7.2$ Hz, 1-CH, 5-CH), 7.536–7.506 (t, 2H, $J = 7.2$ Hz, 2-CH, 4-CH), 7.472–7.443 (t, 1H, $J = 7.2$ Hz, 3-CH), 5.701 (s, 2H, 14- CH_2); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 190.87 (C13), 164.28 (C15), 150.81 (C19), 146.95 (C7), 139.53 (C6), 134.86 (C16), 132.63 (C10), 131.15 (C17, C21), 129.07 (C9, C11), 128.57 (C3), 128.43 (C2, C4), 127.63 (C8, C12), 127.31 (C1, C5), 123.65 (C18, C20), 67.05 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 2-aminobenzoate (2o): Solvent for growing crystal: acetone, ethanol and acetonitrile (1:1:1 v/v); Yield: 73%; M.P. 445–447 K; FT-IR (ATR (solid) cm^{-1}): 3479, 3368 (N-H, v), 3058 (Ar C-H, v), 2933 (C-H, v), 1688 (C = O, v), 1619, 1423 (Ar, C-C, v), 1603 (N-H, δ), 1232, 1145 (C-O, v); ^1H NMR (500 MHz, CDCl_3): δ 8.093–8.076 (d, 2H, $J = 8.6$ Hz, 9-CH, 11-CH), 8.065–8.048 (d, 1H, $J = 8.4$ Hz, 21-CH), 7.767–7.750 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.678–7.663 (d, 2H, $J = 7.3$ Hz, 1-CH, 5-CH), 7.530–7.500 (t, 2H, $J = 7.3$ Hz, 2-CH, 4-CH), 7.462–7.433 (t, 1H, $J = 7.3$ Hz, 3-CH), 7.350–7.316 (t, 1H, $J = 8.4$ Hz, 19-CH), 6.735–6.706 (m, 2H, 18-CH, 20-CH), 5.592 (s, 2H, 14- CH_2); ^{13}C NMR (125 MHz, CDCl_3): δ ppm 192.01 (C13), 167.36 (C15), 150.67 (C17), 146.61 (C7), 139.67 (C6), 134.59 (C19), 133.00 (C10), 131.67 (C21), 129.03 (C9, C11), 128.49 (C2, C4), 128.45 (C3), 127.53 (C8, C12), 127.32 (C1, C5), 116.76 (C18), 116.51 (C20), 110.10 (C16), 66.08 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 3-aminobenzoate (2p): Solvent for growing crystal: acetone, ethanol (1:1 v/v); Yield: 78%; M.P. 424–426 K; FT-IR (ATR (solid) cm^{-1}): 3458, 3356 (N-H, v), 3038 (Ar C-H, v), 2939 (C-H, v), 1707, 1685 (C = O, v), 1632, 1403 (Ar, C-C, v), 1602 (N-H, δ), 1303, 1223, 1110 (C-O, v); ^1H NMR (500 MHz, CDCl_3): δ ppm 8.083–8.066 (d, 2H,

$J = 8.6$ Hz, 9-CH, 11-CH), 7.764–7.747 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.673–7.657 (d, 2H, $J = 7.4$ Hz, 1-CH, 5-CH), 7.581–7.566 (d, 1H, $J = 7.8$ Hz, 21-CH), 7.528–7.498 (t, 1H, $J = 7.4$ Hz, 2-CH, 4-CH), 7.486 (s, 1H, 17-CH), 7.460–7.431 (t, 1H, $J = 7.4$ Hz, 3-CH), 7.297–7.265 (t, 1H, $J = 7.8$ Hz, 20-CH), 6.936–6.920 (d, 1H, $J = 7.8$ Hz, 19-CH), 5.608 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 191.88 (C13), 165.29 (C15), 152.04 (C18), 146.01 (C7), 139.74 (C6), 135.75 (C10), 130.40 (C20), 129.41 (C16), 129.06 (C9, C11), 128.58 (C2, C4), 128.48 (C3), 127.54 (C8, C12), 127.33 (C1, C5), 120.21 (C19), 119.89 (C21), 116.12 (C16), 66.45 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-aminobenzoate (2q): Solvent for growing crystal: acetone Yield: 83%; M.P. 477–479 K; FT-IR (ATR (solid) cm⁻¹): 3437, 3342, 3219 (N–H, ν), 3028 (Ar C–H, ν), 2931 (C–H, ν), 1683 (C = O, ν), 1629, 1419 (Ar, C–C, ν), 1594 (N–H, δ), 1282, 1236, 1169, 1126 (C–O, ν); ¹H NMR (500 MHz, CDCl₃): δ ppm 8.082–8.065 (d, 2H, $J = 8.5$ Hz, 9-CH, 11-CH), 7.999–7.981 (d, 2H, $J = 8.8$ Hz, 17-CH, 21-CH), 7.754–7.737 (d, 2H, $J = 8.5$ Hz, 8-CH, 12-CH), 7.669–7.655 (d, 2H, $J = 7.2$ Hz, 1-CH, 5-CH), 7.524–7.494 (t, 2H, $J = 7.2$ Hz, 2-CH, 4-CH), 7.455–7.426 (t, 1H, $J = 7.2$ Hz, 3-CH), 6.705–6.688 (d, 2H, $J = 8.8$ Hz, 18-CH, 20-CH), 5.568 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 191.66 (C13), 166.18 (C15), 151.22 (C18), 146.01 (C7), 139.74 (C6), 133.00 (C10), 132.16 (C17, C21), 129.02 (C9, C11), 128.49 (C2, C4), 128.40 (C3), 127.49 (C8, C12), 127.32 (C1, C5), 118.90 (C16), 113.85 (C18, C20), 66.21 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl picolinate (2r): Solvent for growing crystal: acetone, acetonitrile (1:1 v/v); Yield: 77%; M.P. 389–391 K; FT-IR (ATR (solid) cm⁻¹): 3061 (Ar C–H, ν), 2931 (C–H, ν), 1741, 1717, 1693 (C = O, ν), 1603, 1404 (Ar, C–C, ν), 1309 (C–N, ν) 1234, 1131 (C–O, ν); ¹H NMR (500 MHz, CDCl₃): δ ppm 8.851–8.837 (d, 1H, $J = 7.5$ Hz, 17-CH), 8.277–8.262 (d, 1H, $J = 7.5$ Hz, 20-CH), 8.085–8.068 (d, 2H, $J = 8.5$ Hz, 9-CH, 11-CH), 7.935–7.904 (t, 1H, $J = 7.5$ Hz, 19-CH), 7.766–7.748 (d, 2H, $J = 8.5$ Hz, 8-CH, 12-CH), 7.669–7.655 (d, 2H, $J = 7.2$ Hz, 1-CH, 5-CH), 7.571–7.547 (t, 1H, $J = 7.5$ Hz, 18-CH), 7.526–7.496 (t, 2H, $J = 7.2$ Hz, 2-CH, 4-CH), 7.459–7.430 (t, 1H, $J = 7.2$ Hz, 3-CH) 5.735 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 190.92 (C13), 164.64 (C15), 149.99 (C16), 147.41 (C7), 146.71 (C20), 139.65 (C6), 137.13 (C18), 132.83 (C10), 129.03 (C9, C11), 128.51 (C2, C4), 128.45 (C3), 127.55 (C8, C12), 127.31 (C1, C5), 127.28 (C19), 125.69 (C17), 67.18 (C14).

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl nicotinate (2s): Solvent for growing crystal: acetone, ethanol and acetonitrile (1:1:1 v/v/v); Yield: 72%; M.P. 389–391 K; FT-IR (ATR (solid) cm⁻¹): 3034 (Ar C–H, ν), 2928 (C–H, ν), 1735, 1722, 1696 (C = O, ν), 1595, 1417 (Ar, C–H, ν), 1327 (C–N, ν) 1285, 1134 (C–O, ν); ¹H NMR (500 MHz, CDCl₃): δ ppm 9.483 (s, 1H, 20-CH), 8.989–8.978 (d, 1H, $J = 5.4$ Hz, 19-CH), 8.956–8.940 (d, 1H, $J = 5.4$ Hz, 17-CH), 8.066–8.049 (d, 2H, $J = 8.6$ Hz, 9-CH, 11-CH), 7.978–7.955 (t, 1H, $J = 5.4$ Hz, 18-CH), 7.795–7.778 (d, 2H, $J = 8.6$ Hz, 8-CH, 12-CH), 7.679–7.665 (d, 2H, $J = 7.4$ Hz, 1-CH, 5-CH), 7.540–7.510 (t, 2H, $J = 7.4$ Hz, 2-CH, 4-CH), 7.477–7.448 (t, 1H, $J = 7.4$ Hz, 3-CH) 5.759 (s, 2H, 14-CH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 189.96 (C13), 165.89 (C15), 147.26 (C7), 143.37 (C6), 139.55 (C19), 138.62 (C20), 133.22 (C10), 132.28 (C17), 129.08 (C9, C11), 128.95 (C18), 128.66 (C3), 128.43 (C2, C4), 127.71 (C8, C12), 127.32 (C1, C5) 126.14 (C16), 67.78 (C14).

Anti-tyrosinase assay

The evaluations of anti-tyrosinase activities of biphenyl esters **2(a-s)** were carried out according to the methods reported by Nithitanakool *et al.* (2009) with some modifications [20]. Briefly, the biphenyl esters with concentrations of 50, 100 and 250 $\mu\text{g/mL}$ were diluted with 40 μL of acetone and mixed with 80 μL of mushroom tyrosinase (100 U/mL) in 0.1 M PBS (pH 6.8) solution. A similar volume of acetone with tyrosinase was used as control. Each biphenyl

ester and control was prepared in triplicate. The mixtures were incubated at 37°C for 10 min. Then, 40 μ L of 0.01 M L-DOPA solution was added and further incubated at 37°C for 25 min. The absorbance was measured at 475 nm using a microplate reader. Kojic acid was used as the standard drug. The percentage of inhibition of tyrosinase enzyme was calculated by using the following formula:

$$\% \text{ Inhibition} = \frac{\text{Absorbance of control} - \text{Absorbance of sample}}{\text{Absorbance of control}} \times 100$$

Statistical analysis

The results of anti-tyrosinase assay were expressed as mean \pm standard deviation (SD) and were labeled if $p < 0.05$ by using ANOVA of IBM SPSS Statistics for Windows, Version 23.0 (IBM, New York).

Docking protocol

The crystal structures of tyrosinase from *Bacillus megaterium* (TyrBm) in complex with inhibitor kojic acid (PDB entry: 3NQ1) [21] and biphenyl esters (**2i**, **2o**, **2p**, **2r** and **2s**) were used as target and ligands, respectively, for molecular docking using Genetic Optimization for Ligand Docking (GOLD) package 5.4.1 [22–24]. Genetic algorithm (GA) was used to explore the ligand-protein binding space and the conformational flexibility of ligand inside the protein. A spherical binding site with a radius of 6 Å was used across residues Phe197, Pro201, Asn205 and Arg209 in the active-site entrance. 100 GA runs were carried out and the top 100 ranked docking poses were scored using the Piecewise Linear Potential (PLP) scoring function. Default values were used for all other parameters. The intermolecular interaction of the best scored pose of each ligand was analyzed and illustrated using the Discovery Studio 4.5 software [25].

All spectral, crystallography data, crystal packing and tyrosinase assay data are described in detail in the [S1 Dataset](#).

Results and discussion

Spectroscopic analysis

The IR spectra of biphenyl esters **2(a-s)** showed absorption bands above 3000 cm^{-1} , indicating the presence of unsaturated C–H (benzene and biphenyl) groups, whereas the aromatic $\nu(\text{C}=\text{C})$ were shown near 1600 cm^{-1} and 1410 cm^{-1} . The methyl ($-\text{CH}_3$) and methylene ($-\text{CH}_2-$) group's C–H stretching were observed around 2970 and 2940 cm^{-1} . In addition, distinct $\nu(\text{C}=\text{O})$ and $\nu(\text{C}-\text{O})$ bands were found in the range of 1743–1683 cm^{-1} and 1300–1028 cm^{-1} . Absorption band for aryl halides were revealed at far right of the spectra, near 750 cm^{-1} . The N = O stretching (**2l-2m**), N–H stretching in (**2o-2q**) and C–N stretching in (**2r-2s**) were observed at $\sim 1530 \text{ cm}^{-1}$, $\sim 3450 \text{ cm}^{-1}$ and $\sim 1310 \text{ cm}^{-1}$, respectively [26, 27]. The ^1H NMR spectra showed presences of $-\text{CH}_2-$ protons centering around $\delta \approx 5.65$ ppm and revealed two well-resolved sets of doublet centering around $\delta \approx 8.09$ and 7.77 ppm with the integration values of 2:2, ascribed to the $-\text{CH}-$ protons of second phenyl ring. The first phenyl ring was shown as a doublet and two triplet near $\delta \approx 7.67$, 7.53 and 7.47 ppm with the integration values of 2:2:1. Furthermore, the benzene protons were revealed at down-field region in the ^1H NMR spectra with different set of multiplicity and integration values due to different position of substituent. Biphenyl and benzene rings can be distinguished by their identical J -coupling values.




Fig 2. General scheme of biphenyl esters with torsion angles τ_1 , τ_2 , τ_3 and τ_4 .

doi:10.1371/journal.pone.0170117.g002

In addition, protons of $-\text{CH}_3$ and $-\text{OCH}_3$ substitutions in compounds **2(f-k)** were revealed at the up-field region near $\delta \approx 2.50$ and 3.90 ppm. Based on the integration values, numbers of protons are in agreement with the proposed values. ^{13}C NMR spectra of **2(a-s)** showed three distinct sets of carbonyl carbon, aromatic carbon and saturated carbon signals. In the down-field region, both $\delta(\text{C}=\text{O})$ and $\delta(\text{COO})$ carbonyl signals are centering around $\delta \approx 191$ and 165 ppm, respectively, whereas the $-\text{CH}_2-$ saturated carbon signals are at the up-field region located around $\delta \approx 66$ ppm. The aromatic carbon signals of biphenyl and benzene groups were found in the range of $\delta \approx 152$ to 110 ppm. The $-\text{CH}_3$ and $-\text{OCH}_3$ carbon signals of compounds **2(f-k)** were located in the up-field region centering at $\delta \approx 21$ and 56 ppm, respectively [28, 29].

Single crystal structure commentary

The asymmetric unit (Z') of all studied compounds consists of a crystallographic independent molecule except **2m**, **2r**, and **2s**, which each consists of two crystallographic independent molecules (denoted as molecules *A* and *B*, respectively). The molecular conformation of biphenyl esters (Fig 2, Table 1) can be characterized by four degree-of-freedom, which are torsion angles $\text{C}5-\text{C}6-\text{C}7-\text{C}12$ (τ_1), $\text{C}9-\text{C}10-\text{C}13-\text{C}14$ (τ_2), $\text{C}13-\text{C}14-\text{O}1-\text{C}15$ (τ_3) and $\text{O}1-\text{C}15-\text{C}16-\text{C}17$ (τ_4).

From the classical point of view, the planarity of biphenyl ring is distorted by the non-bonded steric repulsion force between two *ortho*-hydrogen atoms [30]. However, molecular X-ray structure showed τ_1 varied from almost perpendicular ($\tau_1 = -80.25^\circ$ and -109.38° in **2m**) to almost planar ($\tau_1 = 178.39^\circ$ in **2k**) which opposed to the classical view. Instead of steric repulsion force between the *ortho*-hydrogen atoms, the planarity of τ_1 in compounds **2d**, **2i**, **2j**, **2m** and **2p** might be influenced by $\text{C}-\text{H} \cdots \pi$ interaction in the crystal packing. The torsion angle between biphenyl moiety and adjacent carbonyl group, $\text{C}9-\text{C}10-\text{C}13-\text{C}14$ (τ_2), is nearly planar for most of the compounds and the largest deviation from planarity is observed

Table 1. Summary of torsion angles*.

| Compound | Substituent | τ_1 | τ_2 | τ_3 | τ_4 |
|-----------|---------------------|------------------|-----------------|----------------|----------------|
| 2b | 2-chlorobenzene | -176.57 | -160.15 | 70.26 | 172.44 |
| 2c | 3-chlorobenzene | -27.21 | 172.23 | 76.16 | 8.26 |
| 2d | 4-chlorobenzene | 149.13 | 173.43 | 73.32 | 154.95 |
| 2e | 2,4-dichlorobenzene | -151.14 | -175.31 | 77.09 | 174.74 |
| 2g | 3-methylbenzene | -176.21 | 2.23 | 76.32 | 0.04 |
| 2i | 2-methoxybenzene | -127.41 | -170.83 | 77.17 | -148.66 |
| 2j | 3-methoxybenzene | 149.09 | 7.15 | -75.65 | -6.36 |
| 2k | 4-methoxybenzene | 178.39 | -6.54 | -72.21 | -178.03 |
| 2l | 2-nitrobenzene | -177.09 | 6.76 | 76.59 | -101.32 |
| 2m | 3-nitrobenzene | -80.25, -109.38 | 5.94, 164.3 | -79.04, 78.89 | 173.27, 173.28 |
| 2n | 4-nitrobenzene | -178.13 | -5.47 | 83.95 | -158.17 |
| 2o | 2-aminobenzene | 149.63 | -14.78 | 77.31 | 169.15 |
| 2p | 3-aminobenzene | -156.75 | 170.24 | 89.69 | 1.4 |
| 2q | 4-aminobenzene | 161.03 | 12.88 | 71.34 | -5.13 |
| 2r | 2-pyridine | -164.34, -178.05 | -176.66, -33.91 | -78.65, -79.57 | 177.08, -16.00 |
| 2s | 3-pyridine | 141.69, 145.88 | 5.35, 26.92 | 74.9, -77.11 | 16.14, 1.67 |

* τ_1 = Torsion angle of C5—C6—C7—C12; τ_2 = Torsion angle of C9—C10—C13—C14; τ_3 = Torsion angle of C13—C14—O1—C15; τ_4 = Torsion angle of O1—C15—C16—C17.

doi:10.1371/journal.pone.0170117.t001

in molecule *B* of compound **2r** ($\tau_2 = -33.91^\circ$). Torsion angle τ_3 , which interconnecting two carbonyl groups, in phenacyl benzoates tends to adopt two types of conformations, either *synclinal* or *periplanar* [19]. However, τ_3 for all crystals in this report only adopts *synclinal* conformation, ranging from 70.26° to 89.69° , which is similar to adamantyl-based ester derivatives [31]. The torsion angle between carboxylate group and the attached phenyl ring, O1—C15—C16—C17 (τ_4), is observed in the ranges from 0.04° to 16.14° and 101.32° to 178.03° . The torsion angle τ_4 of compound with methoxy- (**2i**) or nitro-substituted (**2l**) at *ortho*-position is largely twisted due to the steric repulsion between *ortho*-substituent and adjacent carbonyl oxygen atom. The benzoate groups of **2b** (2-chlorobenzene), **2d** (2,4-dichlorobenzene) and **2o** (2-aminobenzene) are nearly planar with angle τ_4 of 172.44° , 174.74° and 169.15° , respectively. The *ortho*-amino substituent in **2o** forms a strong intramolecular N—H...O hydrogen bond with the adjacent carbonyl group, featuring a S(6) ring motif.

Crystal packing similarity and structural occupancy

A Cambridge Structure Database (CSD) search using phenacyl benzoate was performed to locate previously reported phenacyl benzoate and adamantyl benzoate derivatives and 58 similar structures were found. In order to identify the effect of the replacement of phenyl ring with relatively more electron rich biphenyl rings on the crystal packing similarity and structure occupancy, sixteen of the present biphenyl benzoate derivatives were compared with 42 reported phenacyl benzoate derivatives and sixteen adamantyl benzoate derivatives. In contrast to the high occurrence of isostructures in adamantanyl benzoate derivatives [31], there is only a pair of isostructural crystals (**2d** and **2o**) (Fig 3) is observed in the present work.

The comparison of crystal structure occupancy between the search results and the present compounds are summarized in Table 2. The introduction of adamantane moiety in phenacyl benzoate had reduced the occurrence of $\pi\cdots\pi$ interactions as compared to phenacyl benzoates which consist of two terminal phenyl rings. In this study, the replacement of adamantane




Fig 3. Partial crystal packing of 2d and 2o and their overlay diagram.

doi:10.1371/journal.pone.0170117.g003

moiety with biphenyl moiety encouraged the formation of weak intermolecular $\pi \cdots \pi$ and C–H $\cdots\pi$ interactions in crystal packing. Thus, the packing coefficient of most of the present compounds (12 out of 16) laid above 64% and some are even higher than phenacyl benzoates (**2c** = 71%, **2m** = 75% and **2r** = 77%) (Fig 4).

Anti-tyrosinase activities

In the present study, all synthesized compounds were screened for tyrosine inhibitory activity. Five out of nineteen compounds (**2i**, **2o**, **2p**, **2r** and **2s**) with electron-donating substituents (–methoxy &–amino) and pyridine ring showed positive results. The anti-tyrosinase effects of biphenyl esters were evaluated at concentrations of 50, 100 and 250 $\mu\text{g/mL}$. The percentage of inhibition against tyrosinase enzyme of **2i**, **2o**, **2p**, **2r** and **2s** are presented in Fig 5. At the concentration of 250 $\mu\text{g/mL}$, compounds **2p** (3-amino), **2r** (2-pyridine) and **2s** (3-pyridine) showed strong activities with inhibition percentage of 57.33%, 58.90% and 60.34%, respectively, which are comparable to standard drug, kojic acid (57.22%), with no statistical difference. On the other hand, all five active compounds showed an average inhibition percentage

Table 2. Summary of structural occupancy of present and reported compounds.

| Compound | Packing coefficient (%) | Compound | Packing coefficient (%) | Compound | Packing coefficient (%) |
|-------------|-------------------------|-------------|-------------------------|---------------|-------------------------|
| 2b | 64.59 | BUTPOX[31] | 61.08 | EVEGOC[32] | 63.22 |
| 2c | 71.73 | BUTPUD[31] | 61.07 | EVEVEH[33] | 63.04 |
| 2d | 65.37 | BUTQAK[31] | 61.85 | GARCEJ[34] | 65.80 |
| 2e | 63.11 | BUTQEO[31] | 63.05 | GITHUN[35] | 64.40 |
| 2g | 63.28 | BUTQIS[31] | 61.24 | IDIWID [36] | 65.26 |
| 2i | 65.07 | BUTQOY[31] | 61.81 | KULLIO [37] | 62.07 |
| 2j | 66.93 | BUTQUE[31] | 60.61 | MANGIR[38] | 61.06 |
| 2k | 63.76 | AZULUD[39] | 63.85 | OBOYIP[40] | 67.22 |
| 2l | 65.74 | BOQXOW [41] | 66.55 | OCAKUA [42] | 63.92 |
| 2m | 75.69 | CIQNEW[43] | 64.07 | OCAQUG[44] | 66.98 |
| 2n | 64.99 | CIXVUC[19] | 63.94 | OCEFEJ[45] | 68.55 |
| 2o | 62.42 | CIXWAJ[19] | 64.33 | PAXCOI [46] | 66.18 |
| 2p | 67.17 | CIXWEN[19] | 62.08 | PECZAA[47] | 64.37 |
| 2q | 68.61 | CIXWIR[19] | 63.98 | PODQIK[48] | 60.66 |
| 2r | 77.33 | CIYCAQ[19] | 67.27 | PODRAD [49] | 63.77 |
| 2s | 64.42 | CIYCEU[19] | 65.07 | USIWID[50] | 62.53 |
| BUVCIG[31] | 61.11 | CIYCIY[19] | 68.83 | USIWID01 [51] | 62.37 |
| BUVCOM[31] | 61.32 | CIYCOE[19] | 62.96 | USIWOJ[52] | 66.04 |
| BUVCUS[31] | 62.33 | CIYFUN[19] | 62.38 | VOBYUI[53] | 63.97 |
| BUVDAZ[31] | 62.53 | CIYGAU[19] | 64.89 | WIGTUD [54] | 64.99 |
| BUVDED[31] | 60.79 | EVAFOX[55] | 68.00 | YAFWEJ[56] | 66.25 |
| BUVDIH [31] | 60.97 | EVAJAN[57] | 65.64 | YAFZAI[58] | 68.65 |
| BUVDON[31] | 61.68 | EVAJIV[59] | 64.03 | YAHGUL[60] | 63.55 |
| BUVDUT[31] | 61.02 | EVAZEH[61] | 63.03 | YAHYOX[62] | 63.37 |
| BUVFAB[31] | 61.58 | EVEGIW[63] | 63.25 | | |

doi:10.1371/journal.pone.0170117.t002

of 50% at 100 µg/mL. All compounds showed weaker effect than kojic acid at 50 µg/mL, except 2s, which is the best inhibitor in this study, able to inhibit 46.24% of tyrosinase enzyme. In summary, biphenyl compounds which consist of *ortho*-/*meta*-amino group and pyridine ring showed significant response towards tyrosinase enzyme inhibition.




Fig 4. Structural occupancy comparison of biphenyl benzoates, phenacyl benzoates and adamantyl benzoates.

doi:10.1371/journal.pone.0170117.g004




Fig 5. The percentage of tyrosinase inhibition (mean±SD) with n = 3. # and * indicate p<0.05.

doi:10.1371/journal.pone.0170117.g005

Docking and structure-activity relationship

In the protein crystal structure of 3NQ1, inhibitor kojic acid was bound to the active-site entrance of protein TyrBm with hydrogen bond and C-H... π interaction, involving residues Gly200, Arg209 and Pro201 (Fig 6a). The docking models of active compounds **2i**, **2o**, **2p**, **2r** and **2s** are illustrated in Fig 6b and 6f. The first phenyl ring in biphenyl moiety was bound to the copper binding site via C-H... π and π ... π interactions with residues His208 and Val218 (additional C-H... π interaction with residue Ala221 for ligand **2s**), while the second phenyl ring in biphenyl moiety was bound to residue Arg209 through C-H... π interaction. For compounds **2i** and **2o**, their carbonyl moiety was bound with residue Gly200 but the substituted phenyl ring failed to bind with other residues at the active-site entrance (except Met184 for compound **2i**) and this leads to a decrease in enzyme inhibition activities. For compound **2p**, its amino benzene moiety was bound with two residues (Met184 and Phe197) via C-H... π interaction, thus exhibiting stronger inhibition effects than **2i** and **2o**. Similar to kojic acid, the compounds **2r** and **2s**, which showed the strongest activities, contain electron donating pyridine ring that are able to bind with both Pro201 and Gly200 residues at the active-site entrance. The docking results showed that the compound with biphenyl moiety are able to penetrate the active-site entrance and bind to the copper binding site (Ala221, His208 and Val218) by using the advantage of electron mobilized benzene ring, in succession suggesting that the key for strong tyrosinase inhibition effects are the attached heterocyclic ring which are able to shield the active-site entrance by binding itself with residue Pro201 and Gly200.




Fig 6. (a) Kojic acid binding mode in the crystal structure of TyrBm. Putative binding mode inside the binding gorge of TyrBm of ligands: (b) **2i**, (c) **2o**, (d) **2p**, (e) **2r** and (f) **2s**.

doi:10.1371/journal.pone.0170117.g006

Conclusion

A series of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl benzoates, **2(a-q)**, and 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl pyridinecarboxylate, **2(r-s)**, were synthesized and characterized by FTIR, ^1H and ^{13}C NMR spectroscopic analysis, its 3D structure was further confirmed by single-crystal X-ray diffraction studies. Introduction of biphenyl moiety into the synthesis of 2-oxopropyl benzoate derivatives produced crystal structure with higher structural occupancy by augment of the weak $\pi\cdots\pi$ and C-H $\cdots\pi$ interactions. Five compounds showed tyrosine inhibitory activities, while at 250 $\mu\text{g}/\text{mL}$, **2p**, **2r**, and **2s** exhibited high inhibition comparable to the standard drug, kojic acid. In addition, the computational molecular docking results suggested pyridine ring has a better binding affinity toward TyrBm. Thus, further modification of biphenyl compounds substituted with heterocyclic ring can potentially produce promising anti-tyrosinase agents for clinical use in the future.

Supporting information

S1 Dataset.
(DOCX)

Acknowledgments

HCK thanks Malaysian Government for MyBrain15 (MyPhD) scholarship and wish to offer his deep gratitude to Ivy Ye Wei Ng, student from School of Biosciences, Taylor's University, Malaysia for anti-tyrosinase assay data collection. The authors thank the Malaysian Government and Universiti Sains Malaysia (USM) for the Fundamental Research Grant Scheme (FRGS) (203.PFIZIK.6711563).

Author Contributions

Conceptualization: HCK CSCK.

Data curation: HCK ZHL.

Formal analysis: HCK TSC SC.

Funding acquisition: CKQ.

Investigation: CSCK SHM TSC.

Methodology: HCK CSCK.

Project administration: CKQ.

Resources: CKQ SHM GKL.

Software: CKQ.

Supervision: CKQ GKL.

Validation: HCK TSC.

Visualization: HCK TSC.

Writing – original draft: HCK SHM.

Writing – review & editing: HCK CSCK TSC.

References

1. Putschögl FM, Gaum PM, Schettgen T, Kraus T, Gube M, Lang J. Effects of occupational exposure to polychlorinated biphenyls on urinary metabolites of neurotransmitters: A cross-sectional and longitudinal perspective. *Int J Hyg Environ Health*. 2015; 218(5):452–60. <http://dx.doi.org/10.1016/j.ijheh.2015.03.009>. PMID: 25869187
2. Yamamura K, Ono S, Tabushi I. New liquid crystals having 4,4'-biphenanthryl core. *Tetrahedron Letters*. 1988; 29(15):1797–8. [http://dx.doi.org/10.1016/S0040-4039\(00\)82046-8](http://dx.doi.org/10.1016/S0040-4039(00)82046-8).
3. Hohnholz D, Schweikart KH, Subramanian LR, Wedel A, Wischert W, Hanack M. Synthesis and studies on luminescent biphenyl compounds. *SynMe*. 2000; 110(2):141–52. [http://dx.doi.org/10.1016/S0379-6779\(99\)00291-X](http://dx.doi.org/10.1016/S0379-6779(99)00291-X).
4. Bakheit AHH, Abd-Elgalil AA, Mustafa B, Haque A, Wani TA. Chapter Six—Telmisartan. In: Harry GB, editor. *Profiles of Drug Substances, Excipients and Related Methodology*. Volume 40: Academic Press; 2015. p. 371–429.
5. Diflunisal A2—Aronson J.K. *Meyley's Side Effects of Drugs (Sixteenth Edition)*. Oxford: Elsevier; 2016. p. 976.

6. Mutahir S, Jończyk J, Bajda M, Khan IU, Khan MA, Ullah N, et al. Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies. *Bioorg Chem.* 2016; 64:13–20. <http://dx.doi.org/10.1016/j.bioorg.2015.11.002>. PMID: [26595185](https://pubmed.ncbi.nlm.nih.gov/26595185/)
7. Ding Y, Mao L, Xu D, Xie H, Yang L, Xu H, et al. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents. *Bioorganic & Medicinal Chemistry Letters.* 2015; 25(14):2744–8. <http://dx.doi.org/10.1016/j.bmcl.2015.05.040>.
8. Cincinelli R, Zwick V, Musso L, Zuco V, De Cesare M, Zunino F, et al. Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity. *European Journal of Medicinal Chemistry.* 2016; 112:99–105. <http://dx.doi.org/10.1016/j.ejmech.2016.02.001>. PMID: [26890116](https://pubmed.ncbi.nlm.nih.gov/26890116/)
9. Kong XW, Zhang YH, Dai L, Ji H, Lai YS, Peng SX. Synthesis and biological evaluation of nitric oxide-releasing sixalkoxyl biphenyl derivatives as anticancer agents. *Chinese Chemical Letters.* 2008; 19(2):149–52. <http://dx.doi.org/10.1016/j.ccl.2007.11.025>.
10. Dong J, Pan X, Wang J, Su P, Zhang L, Wei F, et al. Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents. *European Journal of Medicinal Chemistry.* 2015; 101:780–9. <http://dx.doi.org/10.1016/j.ejmech.2015.07.015>. PMID: [26231079](https://pubmed.ncbi.nlm.nih.gov/26231079/)
11. Brudeli B, Andressen KW, Moltzau LR, Nilsen NO, Levy FO, Klaveness J. Acidic biphenyl derivatives: Synthesis and biological activity of a new series of potent 5-HT₄ receptor antagonists. *Bioorganic & Medicinal Chemistry.* 2013; 21(22):7134–45. <http://dx.doi.org/10.1016/j.bmc.2013.09.004>.
12. Gargano EM, Perspicace E, Carotti A, Marchais-Oberwinkler S, Hartmann RW. Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17 β -hydroxysteroid dehydrogenase type 2 inhibitors. *Bioorganic & Medicinal Chemistry Letters.* 2016; 26(1):21–4. <http://dx.doi.org/10.1016/j.bmcl.2015.11.047>.
13. Bao K, Dai Y, Zhu Z-B, Tu F-J, Zhang W-G, Yao X-S. Design and synthesis of biphenyl derivatives as mushroom tyrosinase inhibitors. *Bioorganic & Medicinal Chemistry.* 2010; 18(18):6708–14. <http://dx.doi.org/10.1016/j.bmc.2010.07.062>.
14. Dai Y, Zhou G-x, Kurihara H, Ye W-c, Yao X-s. Biphenyl Glycosides from the Fruit of *Pyracantha fortuneana*. *J Nat Prod.* 2006; 69(7):1022–4. doi: [10.1021/np0600853](https://doi.org/10.1021/np0600853) PMID: [16872137](https://pubmed.ncbi.nlm.nih.gov/16872137/)
15. Nakamura K, Yoshida M, Uchiwa H, Kawa Y, Mizoguchi M. Down-Regulation of Melanin Synthesis by a Biphenyl Derivative and Its Mechanism. *Pigment Cell Res.* 2003; 16(5):494–500. PMID: [12950726](https://pubmed.ncbi.nlm.nih.gov/12950726/)
16. Chang T-S. An Updated Review of Tyrosinase Inhibitors. *Int J Mol Sci.* 2009; 10(6):2440. doi: [10.3390/ijms10062440](https://doi.org/10.3390/ijms10062440) PMID: [19582213](https://pubmed.ncbi.nlm.nih.gov/19582213/)
17. Bruker. APEX2, SAINT and SADABS. Bruker AXS Inc, Madison 2009.
18. Sheldrick GM. A short history of SHELX. *A short history of SHELX.* 2008; A64:112–22.
19. Kumar Chandrāju Sadolalu C, Chia Tze S, Ooi Chin W, Quah Ching K, Chandrāju S, Fun H-K. Conformational studies of 2-(4-bromophenyl)-2-oxoethyl benzoates. *Zeitschrift für Kristallographie—Crystal-line Materials* 2014. p. 328.
20. Nithitanakool S, Pithayanukul P, Bavovada R, Saparpakorn P. Molecular Docking Studies and Anti-Tyrosinase Activity of Thai Mango Seed Kernel Extract. *Molecules.* 2009; 14(1):257. doi: [10.3390/molecules14010257](https://doi.org/10.3390/molecules14010257) PMID: [19136913](https://pubmed.ncbi.nlm.nih.gov/19136913/)
21. Sendovski M, Kanteev M, Ben-Yosef VS, Adir N, Fishman A. First Structures of an Active Bacterial Tyrosinase Reveal Copper Plasticity. *J Mol Biol.* 2011; 405(1):227–37. <http://dx.doi.org/10.1016/j.jmb.2010.10.048>. PMID: [21040728](https://pubmed.ncbi.nlm.nih.gov/21040728/)
22. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. *J Mol Biol.* 1995; 245(1):43–53. [http://dx.doi.org/10.1016/S0022-2836\(95\)80037-9](http://dx.doi.org/10.1016/S0022-2836(95)80037-9). PMID: [7823319](https://pubmed.ncbi.nlm.nih.gov/7823319/)
23. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking1. *J Mol Biol.* 1997; 267(3):727–48. <http://dx.doi.org/10.1006/jmbi.1996.0897>. PMID: [9126849](https://pubmed.ncbi.nlm.nih.gov/9126849/)
24. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein—ligand docking using GOLD. *Proteins: Structure, Function, and Bioinformatics.* 2003; 52(4):609–23.
25. Discovery Studio v4.5.0.15071. Accelrys Inc. 2015.
26. Coates J. Interpretation of Infrared Spectra, A Practical Approach. *Encyclopedia of Analytical Chemistry*: John Wiley & Sons, Ltd; 2006.
27. Moorthy JN, Venkatakrisnan P, Samanta S. Novel photochromism of differently-linked bis-benzopyrans. *Organic & Biomolecular Chemistry.* 2007; 5(9):1354–7.

28. Wu Y, Choy PY, Kwong FY. Direct intermolecular C-H arylation of unactivated arenes with aryl bromides catalysed by 2-pyridyl carbinol. *Organic & Biomolecular Chemistry*. 2014; 12(35):6820–3.
29. Marciasini L, Richey N, Vaultier M, Pucheault M. Aminoborylation/Suzuki-Miyaura tandem cross coupling of aryl iodides as efficient and selective synthesis of unsymmetrical biaryls. *Chemical Communications*. 2012; 48(10):1553–5. doi: [10.1039/c1cc14605j](https://doi.org/10.1039/c1cc14605j) PMID: 21959555
30. Poater J, Solà M, Bickelhaupt FM. Hydrogen—Hydrogen Bonding in Planar Biphenyl, Predicted by Atoms-In-Molecules Theory, Does Not Exist. *Chemistry—A European Journal*. 2006; 12(10):2889–95.
31. Kumar C, Kwong H, Mah S, Chia T, Loh W-S, Quah C, et al. Synthesis and Crystallographic Insight into the Structural Aspects of Some Novel Adamantane-Based Ester Derivatives. *Molecules*. 2015; 20(10):18827. doi: [10.3390/molecules201018827](https://doi.org/10.3390/molecules201018827) PMID: 26501248
32. Fun H-K, Quah CK, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Bromophenyl)-2-oxoethyl 2-methoxybenzoate. *Acta Crystallographica Section E*. 2011; 67(7):o1724.
33. Fun H-K, Shahani T, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Chlorophenyl)-2-oxoethyl benzoate. *Acta Crystallographica Section E*. 2011; 67(7):o1802.
34. Isloor AM, Garudachari B, Satyanarayan MN, Gerber T, Hosten E, Betz R. 2-(4-Fluorophenyl)-2-oxoethyl 2-methoxybenzoate. *Acta Crystallographica Section E*. 2012; 68(2):o513.
35. Jin Y, Guo J-N, Lin K, Tang G, Zhao Y-F. Benzoylmethyl 4-chlorobenzoate. *Acta Crystallographica Section E*. 2008; 64(2):o507.
36. Garudachari B, Isloor AM, Gerber T, Hosten E, Betz R. 2-(4-Bromophenyl)-2-oxoethyl naphthalene-1-carboxylate. *Acta Crystallographica Section E*. 2013; 69(5):o649.
37. Diwaker, Chidan Kumar CS, Kumar A, Chandraju S, Fun H-K, Quah CK. Synthesis, spectroscopic characterization and computational studies of 2-(4-bromophenyl)-2-oxoethyl 3-methylbenzoate by density functional theory. *Journal of Molecular Structure*. 2015; 1092:192–201. <http://dx.doi.org/10.1016/j.molstruc.2015.03.028>.
38. Komarov IV, Gorichko MV, Shishkin OV, Kornilov MY. Short Communications—Unusual By-product in the Bromination of 3,3-Dibromocamphor. *Russian journal of organic chemistry*. 1999; 35(9):1388–9.
39. Fun H-K, Shahani T, Garudachari B, Isloor AM, Shivananda KN. 2-(4-Chlorophenyl)-2-oxoethyl 4-hydroxybenzoate. *Acta Crystallographica Section E*. 2011; 67(10):o2682.
40. Fun H-K, Shahani T, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Bromophenyl)-2-oxoethyl 4-methylbenzoate. *Acta Crystallographica Section E*. 2011; 67(12):o3154.
41. Khan I, Ibrar A, Hameed S, White JM, Simpson J. Crystal structure of 2-(4-chlorophenyl)-2-oxoethyl 3-bromobenzoate. *Acta Crystallographica Section E*. 2014; 70(11):301–4.
42. Fun H-K, Quah CK, Vijesh AM, Isloor AM, Arulmoli T. 2-(4-Chlorophenyl)-2-oxoethyl 3,4-dimethoxybenzoate. *Acta Crystallographica Section E*. 2011; 67(12):o3351.
43. Ji T, Wang X-L, Gao Y-X, Tang G, Zhao Y-F. Benzoylmethyl 4-methoxybenzoate. *Acta Crystallographica Section E*. 2007; 63(12):o4766.
44. Fun H-K, Chia TS, Shenvi S, Isloor AM, Garudachari B. 2-(2,4-Dichlorophenyl)-2-oxoethyl 4-methoxybenzoate. *Acta Crystallographica Section E*. 2011; 67(12):o3379.
45. Fun H-K, Loh W-S, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Fluorophenyl)-2-oxoethyl 4-methoxybenzoate. *Acta Crystallographica Section E*. 2011; 67(12):o3456.
46. Fun H-K, Asik SIJ, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Bromophenyl)-2-oxoethyl anthracene-9-carboxylate. *Acta Crystallographica Section E*. 2012; 68(6):o1876.
47. Khan I, Ibrar A, Korzanski A, Kubicki M. 2-(4-Methylphenyl)-2-oxoethyl 3-bromobenzoate. *Acta Crystallographica Section E*. 2012; 68(12):o3465.
48. Chidan Kumar CS, Yohannan Panicker C, Fun H-K, Sheena Mary Y, Harikumar B, Chandraju S, et al. Molecular structure, FT-IR, first order hyperpolarizability, NBO analysis, HOMO and LUMO analysis of 2-(4-chlorophenyl)-2-oxoethyl 3-methylbenzoate by HF and density functional methods. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2014; 128(0):327–36. <http://dx.doi.org/10.1016/j.saa.2014.02.185>.
49. Chidan Kumar CS, Panicker CY, Fun H-K, Mary YS, Harikumar B, Chandraju S, et al. FT-IR, molecular structure, first order hyperpolarizability, HOMO and LUMO analysis, MEP and NBO analysis of 2-(4-chlorophenyl)-2-oxoethyl 3-nitrobenzoate. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2014; 126(0):208–19. <http://dx.doi.org/10.1016/j.saa.2014.01.145>.
50. Fun H-K, Arshad S, Garudachari B, Isloor AM, Satyanarayan MN. 2-Oxo-2-phenylethyl benzoate. *Acta Crystallographica Section E*. 2011; 67(6):o1528.
51. Khamarui S, Maiti R, Maiti DK. General base-tuned unorthodox synthesis of amides and ketoesters with water. *Chemical Communications*. 2015; 51(2):384–7. doi: [10.1039/c4cc07961b](https://doi.org/10.1039/c4cc07961b) PMID: 25406587

52. Fun H-K, Loh W-S, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Bromophenyl)-2-oxoethyl 4-methoxybenzoate. *Acta Crystallographica Section E*. 2011; 67(6):o1529.
53. Chidan Kumar CS, Fun HK, Tursun M, Ooi CW, Chandraju S, Quah CK, et al. Synthesis, molecular structure, FT-IR and XRD investigations of 2-(4-chlorophenyl)-2-oxoethyl 2-chlorobenzoate: A comparative DFT study. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2014; 124(0):595–602. <http://dx.doi.org/10.1016/j.saa.2014.01.063>.
54. Garudachari B, Isloor AM, Gerber T, Hosten E, Betz R. 2-(4-Chlorophenyl)-2-oxoethyl naphthalene-1-carboxylate. *Acta Crystallographica Section E*. 2013; 69(4):o551.
55. Fun H-K, Arshad S, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Bromophenyl)-2-oxoethyl 4-bromobenzoate. *Acta Crystallographica Section E*. 2011; 67(7):o1582–o3.
56. Fun H-K, Arshad S, Garudachari B, Isloor AM, Shivananda KN. 2-(4-Fluorophenyl)-2-oxoethyl 3-(trifluoromethyl)benzoate. *Acta Crystallographica Section E*. 2011; 67(11):o2836.
57. Fun H-K, Loh W-S, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Chlorophenyl)-2-oxoethyl 3-(trifluoromethyl)benzoate. *Acta Crystallographica Section E*. 2011; 67(7):o1597.
58. Fun H-K, Loh W-S, Garudachari B, Isloor AM, Satyanarayana MN. 2-(4-Bromophenyl)-2-oxoethyl 4-hydroxybenzoate. *Acta Crystallographica Section E*. 2011; 67(11):o2854.
59. Fun H-K, Arshad S, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Chlorophenyl)-2-oxoethyl 2,4-difluorobenzoate. *Acta Crystallographica Section E*. 2011; 67(7):o1599.
60. Fun H-K, Loh W-S, Garudachari B, Isloor AM, Satyanarayana MN. 2-(4-Chlorophenyl)-2-oxoethyl 4-methylbenzoate. *Acta Crystallographica Section E*. 2011; 67(11):o3030.
61. Fun H-K, Asik SIJ, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Chlorophenyl)-2-oxoethyl 2-methoxybenzoate. *Acta Crystallographica Section E*. 2011; 67(7):o1687.
62. Fun H-K, Ooi CW, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Bromophenyl)-2-oxoethyl 2-methylbenzoate. *Acta Crystallographica Section E*. 2011; 67(11):o3119.
63. Fun H-K, Yeap CS, Garudachari B, Isloor AM, Satyanarayan MN. 2-(4-Bromophenyl)-2-oxoethyl 4-chlorobenzoate. *Acta Crystallographica Section E*. 2011; 67(7):o1723.